Generex Biotechnology, Contract Research Organization to Manage Global Phase III Trials For Generex Oral-lyn

Oct. 16, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has entered into a number of key service agreements for its global Phase III trials for Generex Oral-lyn, its proprietary oral insulin spray product... Generex Biotechnology's Press Release -